Nearly 12 percent of India’s eligible children received no dose of measles vaccine: Study

New Delhi: Nearly 12 percent of children in India who are eligible for measles vaccination have received none of the recommended double-dose, signalling a “concerning gap” in immunisation coverage, a new study has found. The findings showed that zero-dose cases were high in the northeastern states, with Nagaland reporting the greatest share at 26 per cent. Tamil Nadu was found to report the lowest at 4.6 per cent.

Researchers from the Ministry of Health and Family Welfare and Banaras Hindu University in Varanasi investigated previously overlooked critical aspects of measles vaccination, focusing on zero-doses, partially vaccinated, and those fully immunised. They analysed data of over 43,000 children aged 2-3 years, collected through the National Family Health Survey 2019-21 (NFHS-5).

The team found that close to 30 per cent of the eligible children have received only one measles-containing vaccine (MCV1), while about 60 per cent have been fully immunised (MCV2). The findings are published in the journal Vaccine.

In 2017, India adopted the National Strategic Plan for Achieving and Sustaining Measles and Rubella Elimination. The researchers acknowledged that disruptions due to the COVID-19 pandemic heightened the risk of measles in vulnerable populations.

While immunisation programmes were eventually resumed in a phased manner, measles zero-dose children pose a significant obstacle to achieving goals of eliminating the acute and highly contagious viral disease, the researchers said. Occurring primarily in children, symptoms can include high fever, cough, runny nose and a rash all over the body.

Being vaccinated is the best way to avoid getting sick and spreading the disease, according to the World Health Organization.

The analysis also revealed huge inter-district variations, according to the researchers. They found that in Uttar Pradesh, while Prayagraj and Banda districts were found to have about 34 per cent and 32 per cent of these cases, respectively, Hapur and Etawah have 2.6 per cent and 2.1 per cent of zero-dose cases.

The researchers said Arunachal Pradesh was another such example, where the West Siang district had the greatest share with almost 50 per cent of eligible children receiving no dose of the vaccination, while the Lower Dibang Valley district had only 2.8 per cent of such cases.

Socio-demographic factors were analysed to influence the measles vaccination status of children, with those born later in the family being less likely to have received no dose.

Low levels of wealth and mother’s education too were found to increase the odds of children not receiving any dose of the vaccination.

Vaccine hesitancy, possibly influenced by culture and misinformation, can also lead to lower inoculation rates, the researchers said.

“Socioeconomic factors play a significant role in measles transmission, with individuals from lower socioeconomic classes experiencing higher attack rates resulting in outbreaks,” the authors wrote.

The findings underscored the need for tailored strategies, especially within districts displaying close to 10 per cent variability in zero-dose cases, the researchers said.

“The identification of a notable percentage (11.5 per cent) of children receiving zero-doses signals a concerning gap in immunisation coverage,” the authors wrote.

“This highlights the importance of last mile effort and application of big push theory in terms of more frequent rounds of campaigns mode vaccine delivery for the target of 95 per cent vaccine coverage for population-level immunity,” they wrote.

Powered by WPeMatico

Removing gut bacteria’s potential ‘safe house’ may lower risk of colorectal cancer subtype

The appendix, once dismissed as an unnecessary human organ, has more recently been shown to play a role in the immune system. However, we lack a clear understanding of how its removal to treat appendicitis affects long-term human health.

Powered by WPeMatico

Radiotherapy with hormone therapy can help some advanced prostate cancer patients avoid chemotherapy

Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced prostate cancer, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Powered by WPeMatico

Endoscopic procedure burns stomach lining to reduce ‘hunger hormone’ and lead to weight loss

A new weight-loss treatment could be on the horizon with an innovative endoscopic procedure that ablates (burns) the stomach lining to reduce production of ghrelin, a hormone that triggers hunger, resulting in decreased appetite and significant weight loss, according to a first-in-human trial to be presented at Digestive Disease Week (DDW) 2024.

Powered by WPeMatico

Simple ‘swish-and-spit’ oral rinse could provide early screening for gastric cancer

A simple oral rinse could provide early detection of gastric cancer, the fourth-leading cause of cancer deaths worldwide, according to a study scheduled for presentation at Digestive Disease Week (DDW) 2024.

Powered by WPeMatico

GI procedures can produce dangerous levels of smoke

Health care professionals attending certain smoke-producing endoscopic gastrointestinal procedures, including a procedure that uses electrical current to remove polyps, could be exposed to dangerous toxin levels equivalent to smoking a cigarette during each procedure and face “significant health risks” over their careers, according to a study scheduled for presentation at Digestive Disease Week (DDW) 2024.

Powered by WPeMatico

Stent Bribery Case Exposed at RML Hospital, Two Senior Cardiologists Arrested by CBI

New Delhi: Two senior cardiologists at Dr. Ram Manohar Lohia (RML) Hospital, along with seven other persons were arrested on Wednesday by the Central Bureau of Investigation (CBI) for allegedly demanding and accepting bribes from medical equipment suppliers to use their products and stents.

One of the arrested cardiologists has been identified as Professor Dr Ajay Raj, Professor of Cardiology, ABVIMS and RML hospital while the other is Assistant Professor, Dr Parvatagouda Channappagouda. They allegedly formed a nexus with the medical equipment supplier firms and promoted their products for monetary gains.

Busting the bribery racket, CBI also nabbed the medical equipment supplier Naresh Nagpal of Nagpal Technologies who paid Rs 2.48 lakh to Parvatagouda for promoting the sale of medical equipment, mainly, Bharat Singh Dalal of Bharti Medical Technologies who bribed Raj using UPI twice, and Abrar Ahmed who paid bribes to Cath Lab in charge in the hospital Rajnish Kumar, PTI has reported.

Officials informed that Rajnish Kumar as well as clerks Bhuval Jaiswal, Sanjay Kumar, and Vikas Kumar have also been arrested. The probe agency alleged that Bhuval Jaiswal took bribes for fixing appointments with doctors while Sanjay Kumar took bribes for fake medical certificates.

All arrested accused were produced before a special court which sent them to CBI custody till May 14. At least four private firms based in Delhi and Gurgaon are under CBI scanner, TOI has reported.

More than 13 locations in Delhi and other places were subsequently raised and searched by CBI, which seized around Rs 2.5 lakh cash, gold bars, and lockers of the accused. The Bureau has alleged that the scan was being carried out at multiple levels. Until now, the probe is still at an early stage and more arrests are likely to occur soon.

Also Read: Corruption racket in Safdarjung Hospital: Court grants bail to man accused of extracting money from patients

As per the latest media report by the Times of India, the CBI laid the trap for Dr. Parvathgouda and arrested him red-handed on Tuesday. During its technical surveillance, CBI found that on May 2, the doctor had demanded a bribe from the owner of Nagpal Technologies, one Naresh Nagpal for being allowed to use medical equipment supplied by him.

Commenting on the matter, an official told the Daily, “Dr Parvathgouda asked Nagpal to clear previous month’s dues of bribes because he was leaving for Europe. Nagpal assured him that the amount would be delivered on May 7 at the hospital.”

Based on this communication, the CBI registered an FIR under sections of the Prevention of Corruption Act besides those related to criminal conspiracy on Tuesday. The FIR by CBI stated, “There is a likelihood that Nagpal may deliver the bribe money of Rs 2.48 lakh to Dr Parvathgouda at RML anytime on May 7.”

Accordingly, CBI laid a trap at the RML Hospital, and its sleuths were stationed there in disguise. Already, the movements of Nagpal were being tracked. After he entered the doctor’s cabin, CBI conducted a raid during the alleged exchange of bribes. Another doctor, Professor Ajay Raj was detained on Wednesday based on the investigation. Similarly, based on the probe that followed, the CBI summoned other accused as well and arrested them. One of the accused, Abrar Ahmed fled to Jaipur. However, he was tracked down.

“Information has been received through reliable sources that several doctors and employees of Ram Manohar Lohia Hospital in Delhi have been indulging in corrupt practices and collecting bribes from patients either directly or indirectly through representatives of the companies supplying different equipment required for diagnosis and treatment of patients. Sources have informed that Dr Parvathgouda and Dr. Ajay Raj were blatantly demanding and accepting bribes in pursuance of the conspiracy with Naresh Nagpal in lieu of allowing the use of medical devices to be implanted in patients,” stated the FIR by CBI.

Dr. Parvathgouda completed his MD from RML in 2016 and later joined the hospital in 2021. On the other hand, Dr. Raj has been working at the hospital since 2011 after he completed his MD from another hospital in 2006, TOI has reported.

Meanwhile, the CBI is in the process of summoning the accused from different firms who were in touch with the doctors. Account transactions are being analyzed to ascertain the number of patients who were given stents in exchange for bribes.

Commenting on this, an officer informed the Daily, “We are also probing if the stents were substandard. The patients are being contacted after checking hospital records. Other doctors are being spoken to. We are also probing the price difference of the stents.”

Dr. Ajay Shukla, the director and medical superintendent of the hospital has referred to the arrest of the hospital employees as shocking. He said, “No complaint was filed by any of the patients. We will cooperate with the agency to ensure a fair probe.”

This is the second major operation against a nexus between doctors and medical suppliers in recent times. Medical Dialogues had earlier reported that CBI last year had arrested an associate professor with the Neurosurgery department at the prominent Safdarjung Hospital in New Delhi for allegedly being involved in illegal activities and accepting money in exchange for medical advice.

Back then, CBI had accused the associate professor Dr. Rawat of colluding with his accomplices to extract payment from patients for medical consultations and surgical procedures while flouting the hospital’s established protocols.

Also Read: Corruption Racket Busted in Govt Hospital in Delhi: CBI arrests Neurosurgery Associate Professor of Safdarjung Hospital

Powered by WPeMatico

17-year-old boy poses as patient, places mobile phone in restroom of Kasturba Medical College; arrested

Mangalore: A 17-year-old boy has been arrested by the police after he allegedly entered the premises of Mangaluru’s Kastruba Medical College disguised as a patient and placed a mobile phone inside the women’s restroom. 

The incident came to light on Wednesday when the security personnel discovered the phone after it rang, police said.

According to a PTI report, The college authorities handed over the phone to the police following which the minor was apprehended based on the details available on the phone.

Also Read:Kasturba Medical College signs MoU with CSIR-CDRI for research work on Antimicrobial Resistance

A case has been booked in the North Police Station of the city under the appropriate section of the Indian Penal Code.  

The individual in question purportedly disguised himself as a patient to gain access to the college premises.  

Subsequently, he was presented before the Juvenile Justice Board in accordance with established procedures.  

Powered by WPeMatico

Cipla gets 1 inspectional observation from USFDA for Maha facility

Mumbai: Pharma giant Cipla has informed through a recent BSE filing that the Company has received 1 inspectional observation in Form 483 from the United States Food and Drug Administration (USFDA) at the conclusion of the inspection at Kurkumbh manufacturing facility.

The inspection was held from 29th April, 2024 to 8th May, 2024.

“A routine current Good Manufacturing Practices (cGMP) inspection was conducted by
the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located
in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024,” Cipla stated.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

“The
Company will work closely with the USFDA and is committed to address this observation comprehensively
within stipulated time,” Drug major added.

Read also: Cipla Health to acquire Ivia Beaute’s cosmetics, personal care distribution and marketing business for Rs 130 crore

In April, the Medical Dialogues team reported that Cipla received six inspectional observations in Form 483 from the USFDA at the conclusion of a routine current Good Manufacturing Practices (cGMP) inspection at the company’s manufacturing facility located in Patalganga, Maharashtra, India.  

Read also: Cipla gets 6 USFDA observations for Maha facility

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai. Cipla has extended its presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. The Company is also deepening its presence in the key markets of India, South Africa, and the U.S. among other economies of the emerging world.

Read also: Cipla Gets CDSCO Panel Nod To import, market Human Insulin inhalation powder with inhaler

Powered by WPeMatico

Ertugliflozin Significantly Reduces Functional Mitral Regurgitation in Heart Failure patients : Study

Researchers have found that ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves left ventricular global longitudinal strain and left atrial remodeling, and reduces functional mitral regurgitation (MR) in patients with heart failure (HF). The EFFORT trial assessed the efficacy of ertugliflozin for the reduction of functional MR associated with HF and mild to moderately reduced ejection fraction, offering a potential new treatment option for patients. This study was published in the journal Circulation by Kang and colleagues.

Functional mitral regurgitation (MR) is a common complication in patients with heart failure (HF), contributing to significant morbidity and mortality despite standard medical therapy. The EFFORT trial was a multicenter, double-blind, randomized study examining whether ertugliflozin could improve MR in patients with HF, New York Heart Association functional class II or III, and an ejection fraction between 35% and 50%.

A total of 128 patients were randomly assigned to receive either ertugliflozin or placebo, in addition to guideline-directed medical therapy for HF. The primary endpoint was a change in the effective regurgitant orifice area of functional MR from baseline to the 12-month follow-up. Secondary endpoints included changes in regurgitant volume, left ventricular (LV) volume indices, left atrial volume index, LV global longitudinal strain, and NT-proBNP (N-terminal pro-B-type natriuretic peptide).

The key findings of the study were as follows:

  • The treatment groups were well-matched in baseline characteristics, with mean age 66±11 years and 61% male participants.

  • The decrease in the effective regurgitant orifice area was significantly greater in the ertugliflozin group compared to the placebo group (−0.05±0.06 versus 0.03±0.12 cm2; P<0.001).

  • Ertugliflozin was associated with a reduction in regurgitant volume by 11.2 mL (95% CI, −16.1 to −6.3; P=0.009), a decrease in the left atrial volume index by 6.0 mL/m2 (95% CI, −12.16 to 0.15; P=0.005), and improved LV global longitudinal strain by 1.44% (95% CI, −2.42% to −0.46%; P=0.004).

  • There were no significant between-group differences in LV volume indices, ejection fraction, or NT-proBNP levels.

  • Serious adverse events occurred in 1.6% of ertugliflozin group participants versus 9.2% of the placebo group (P=0.12).

Ertugliflozin demonstrated significant improvement in left ventricular global longitudinal strain and left atrial remodeling, as well as a reduction in functional MR in patients with HF. Sodium-glucose cotransporter 2 inhibitors like ertugliflozin may offer a novel therapeutic approach for patients with functional MR.

Reference:

Duk-Hyun Kang, MD, PhD, Sung-Ji Park, MD, PhD, Sung-Hee Shin, MD, PhD, In-Chang Hwang, MD, Yeonyee Elizabeth Yoon, MD, PhD, Hyung-Kwan Kim, MD, PhD, Mijin Kim, MD, PhD, Min-Seok Kim, MD, PhD, Sung-Cheol Yun, PhD, Jong-Min Song, MD, PhD, Seok-Min Kang, MD, PhD Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT TrialCirculation. 2024;149:00–00. DOI: 10.1161/CIRCULATIONAHA.124.069144

Powered by WPeMatico